Just as the dust had settled around Pfizer’s brief Metsera bidding war with Novo Nordisk, another planned biopharma ...

The updated label now includes a boxed warning and a new “limitation of use" in addition to the removal of the prior ...

As Roche works to switch certain patients with breast cancer over to a fixed-dose combination of two medicines, its ...

Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies ...

Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

An Association of Black Cardiologists (ABC) survey has uncovered a widespread gap in cardiovascular health awareness among ...

On the heels of a private equity buyout campaign that ultimately fell flat, Bavarian Nordic’s board chair is stepping aside.

Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss their observations from the third quarter and put the industry’s ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...

As Lundbeck and Otsuka count on prescriptions in agitation associated with dementia due to Alzheimer’s disease (AADAD) to ...